ASLN
Price:
$0.6
Market Cap:
$1.70M
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was fou...[Read more]
Industry
Biotechnology
IPO Date
2018-05-04
Stock Exchange
NASDAQ
Ticker
ASLN
According to ASLAN Pharmaceuticals Limited’s latest financial reports and current stock price. The company's current PE Ratio is -0.04. This represents a change of -99.78% compared to the average of -18.48 of the last 4 quarters.
The mean historical PE Ratio of ASLAN Pharmaceuticals Limited over the last ten years is -28.73. The current -0.04 PE Ratio has changed -86.08% with respect to the historical average. Over the past ten years (40 quarters), ASLN's PE Ratio was at its highest in in the September 2016 quarter at 49.28. The PE Ratio was at its lowest in in the June 2021 quarter at -84.63.
Average
-28.73
Median
-18.63
Minimum
-129.68
Maximum
-1.55
Discovering the peaks and valleys of ASLAN Pharmaceuticals Limited PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 375.88%
Maximum Annual PE Ratio = -1.55
Minimum Annual Increase = -78.85%
Minimum Annual PE Ratio = -129.68
Year | PE Ratio | Change |
---|---|---|
2023 | -1.55 | -60.22% |
2022 | -3.91 | -76.75% |
2021 | -16.81 | -46.51% |
2020 | -31.43 | 180.48% |
2019 | -11.21 | -45.19% |
2018 | -20.45 | -25.47% |
2017 | -27.43 | -78.85% |
2016 | -129.68 | 249.88% |
2015 | -37.06 | 375.88% |
The current PE Ratio of ASLAN Pharmaceuticals Limited (ASLN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-7.43
5-year avg
-12.98
10-year avg
-28.73
ASLAN Pharmaceuticals Limited’s PE Ratio is greater than Monte Rosa Therapeutics, Inc. (-3.11), greater than NewAmsterdam Pharma Company N.V. (-7.25), greater than Inventiva S.A. (-0.87), greater than Cullinan Oncology, Inc. (-6.96), greater than Compass Therapeutics, Inc. (-4.30), greater than Structure Therapeutics Inc. (-18.15), greater than IO Biotech, Inc. (-0.63), greater than Erasca, Inc. (-3.94), greater than Lyra Therapeutics, Inc. (-0.18), greater than Anebulo Pharmaceuticals, Inc. (-4.99), greater than Mineralys Therapeutics, Inc. (-4.63), greater than AN2 Therapeutics, Inc. (-0.47), greater than Aerovate Therapeutics, Inc. (-0.62), greater than Adagene Inc. (-2.86), greater than Acrivon Therapeutics, Inc. Common Stock (-4.23), greater than Agios Pharmaceuticals, Inc. (-6.74), greater than Assembly Biosciences, Inc. (-2.10), greater than Achilles Therapeutics plc (-0.45), less than CytomX Therapeutics, Inc. (9.19), greater than Instil Bio, Inc. (-0.78), greater than Neoleukin Therapeutics, Inc. (-0.98),
Company | PE Ratio | Market cap |
---|---|---|
-3.11 | $349.21M | |
-7.25 | $1.48B | |
-0.87 | $115.22M | |
-6.96 | $1.04B | |
-4.30 | $196.75M | |
-18.15 | $2.11B | |
-0.63 | $55.60M | |
-3.94 | $807.96M | |
-0.18 | $17.85M | |
-4.99 | $46.68M | |
-4.63 | $558.43M | |
-0.47 | $30.44M | |
-0.62 | $54.85M | |
-2.86 | $115.55M | |
-4.23 | $250.26M | |
-6.74 | $2.46B | |
-2.10 | $107.81M | |
-0.45 | $29.58M | |
9.19 | $93.74M | |
-0.78 | $92.68M | |
-0.98 | $8.20M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ASLAN Pharmaceuticals Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ASLAN Pharmaceuticals Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is ASLAN Pharmaceuticals Limited's PE Ratio?
How is the PE Ratio calculated for ASLAN Pharmaceuticals Limited (ASLN)?
What is the highest PE Ratio for ASLAN Pharmaceuticals Limited (ASLN)?
What is the 3-year average PE Ratio for ASLAN Pharmaceuticals Limited (ASLN)?
What is the 5-year average PE Ratio for ASLAN Pharmaceuticals Limited (ASLN)?
How does the current PE Ratio for ASLAN Pharmaceuticals Limited (ASLN) compare to its historical average?